



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/646,436	08/21/2003	Martin Gleave	UBC.P-030	9171
57381	7590	07/23/2009		
Larson & Anderson, LLC P.O. BOX 4928 DILLON, CO 80435			EXAMINER CHONG, KIMBERLY	
			ART UNIT 1635	PAPER NUMBER
			MAIL DATE 07/23/2009	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/646,436	Applicant(s) GLEAVE ET AL.	
	Examiner KIMBERLY CHONG	Art Unit 1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 April 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,4,10,11,14,20,23 and 29 is/are pending in the application.
- 4a) Of the above claim(s) 20,23 and 29 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,4,10,11,14 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status of Application/Amendment/Claims

Applicant's response filed 04/22/2009 has been considered. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. With entry of the amendment filed on 04/22/2009, claims 1, 4, 10, 11, 14, 20, 23 and 29 are pending in the application. Claims 1, 4, 10, 11 and 14 are currently under examination and claims 20, 23 and 29 are withdrawn as being drawn to a non-elected invention

.Response to Declaration

The declaration filed on 04/22/2009 under 37 CFR 1.132 is insufficient to overcome the rejection of claims 1, 4, 10 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Miyake et al. (Clinical Cancer Research 2000 cited on Applicant's IDS filed 03/31/2004), Tuschl et al. (US 2004/0259247), Fosnaugh et al. (US 2003/0143732) and Hammond et al. (Nature Reviews 2001, Vol. 2; pages 110-119).

According to MPEP 715.04, any affidavit or declaration to overcome a rejection of the claims must be made by the inventor or inventors of the subject matter or a party qualified under 37 CFR 1.42, 1.43 or 1.47. The application as filed does not appear to have a granted petition under 37 CFR 1.47 or appears to have been accepted under 37 CFR 1.42 or 1.43. Thus the affidavit is not proper.

Further, Applicant's representative states that as of July 18, 2002, her files reflect that she possessed the data contained in Tables 1-4 of the filed provisional application and was beginning to prepare the filed provisional application. Without the actual sequences of the RNA molecules provided, the evidence as submitted is not sufficient to establish possession of the claimed subject matter and to overcome the rejection of record.

New Claim Rejections

Claim Rejections - 35 USC § 103

The rejection of claims 1, 4, 10, 11 and 14 under 35 U.S.C. 103(a) as being unpatentable over Miyake et al. (Clinical Cancer Research 2000 cited on Applicant's IDS filed 03/31/2004), Tuschl et al. (US 2004/0259247) and Holen et al. (Nucleic Acid Research 2002).

The instant claims embrace dsRNA and are drawn to a RNA molecule having a sequence effective to mediate degradation or block translation of mRNA of a target gene wherein the target gene encodes a clusterin gene and the RNA molecule comprises a sequence as defined by SEQ ID No. 10 and further drawn to pharmaceutical compositions comprising said RNA molecule together with a pharmaceutically acceptable carrier.

Miyake et al. teach antisense oligonucleotides targeted to clusterin target gene TRPM-2, wherein the antisense oligonucleotide is capable of mediating degradation or blocking translation of the mRNA (see page 1655). Miyake et al. teach prostate cancer

Art Unit: 1635

is a commonly diagnosed malignancy and TRPM-2 has been found to be unregulated in prostate cancer and acts to inhibit apoptosis of said prostate cancer cells (see abstract and page 1655) and inhibition of TRPM-2 gene using antisense oligonucleotides provides a therapeutic treatment for prostate cancer (see page 1659-1662). Miyake et al. further teach screening active antisense oligonucleotides sequences targeted to the human TRPM-2 gene (see page 1659) and specifically identifies an antisense compound as AS ODN#2 which targets the human TRPM-2 translation initiation site as being capable of reducing TRPM-2 expression (see page 1659) which is the target site targeted by the claimed SEQ ID No. 10 sequence.

At the time of filing of the instant invention, it was well known in the art that RNAi using siRNA was becoming a more efficient method of silencing gene expression. Hammond et al. discusses siRNA and previous methods of reducing using inhibitory molecules such as antisense compounds and states that siRNA is a more potent method of silencing gene expression, requiring only a few molecules of siRNA per cell to silence gene expression (see page 110).

Tuschl et al. teach making and using siRNA for mediating gene silencing (see Example 1 and the siRNA User Guide beginning at paragraph 0178) and has demonstrated siRNA mediated silencing in mammalian cells and states that the use of short siRNAs holds great promise for Inactivation of gene function in human tissues and the development of gene-specific therapeutics (see paragraphs 0144-0151).

Holen et al. teach siRNA efficacy is highly dependent on target position and teach the routine nature of identification of an efficient target site by designing multiple

Art Unit: 1635

siRNA that overlap in sequence targeted to a known specific target region of a gene (see at least page 1758).

It would have been obvious to one of skill in the art at the time the invention was made to use the methods taught by Tuschl et al. to make a siRNA targeted to a clusterin/TRPM-2 mRNA for the silencing of gene expression.

One of ordinary skill in the art would have been expected to be able to design an siRNA targeted to the same region as the claimed RNA sequence because Tuschl et al. details the steps to effectively find a target site in any RNA and design and test siRNA molecules for specific RNAi activity. Miyake et al. identifies an optimal target region, a region of TRPM-2 gene that is targeted by the claimed SEQ ID No. 10, one of ordinary skill in the art would have been expected to make the claimed RNA molecule comprising SEQ ID No. 10. Moreover, because Holen et al. demonstrates the routine nature of designing siRNA sequence that target a gene every 3 nucleotides, one of ordinary skill in the art would have designed an RNA molecule targeted to TRPM-2 as taught by Miyake et al.

Tuschl et al. teach that it was well recognized in the art that siRNA was a more efficient method of silencing gene expression, requiring concentrations far less than the methods of the prior art, such as antisense compounds. In looking to reduce gene expression of TRPM-2, one of ordinary skill in the art would have wanted use the most efficient method to silencing gene expression and would have looked to the teachings of Tuschl et al. and Holen et al. for generation of siRNAs targeted to of TRPM-2 mRNA. Tuschl et al. and Holen et al. teach that production of siRNAs to any target gene is a

Art Unit: 1635

matter of routine experimentation and optimization and clearly set forth the guidelines to design such molecules.

Finally, one of ordinary skill in the art would have expected to be able to generate a siRNA targeted to a TRPM-2 gene given Miyake et al. teach an antisense compound targeted to the identical region as the claimed RNA sequence and Tuschl et al. teach the basic steps to identifying any target site and making and screening siRNA molecules for activity, steps that are routine to one of ordinary skill in the art.

Thus in the absence of evidence to the contrary, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Response to Applicant's Arguments

Re: Claim Rejections - 35 USC § 103

The rejection of claims 1, 4, 10 and 11 under 35 U.S.C. 103(a) as being unpatentable over Miyake et al. (Clinical Cancer Research 2000 cited on Applicant's IDS filed 03/31/2004), Tuschl et al. (US 2004/0259247), Fosnaugh et al. (US 2003/0143732) and Hammond et al. (Nature Reviews 2001, Vol. 2; pages 110-119) is maintained for the reasons of record and as explained in the response to the declaration above.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kimberly Chong whose telephone number is 571-272-3111. The examiner can normally be reached Monday thru Friday between 7-4 pm.

Art Unit: 1635

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James (Doug) Schultz can be reached at 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Kimberly Chong/
Primary Examiner
Art Unit 1635